Living with the aftereffects of COVID-19 can cause PTSD.
If you were hospitalized with a life-threatening COVID-19 infection or have lost a family member to COVID-19 and are experiencing unwanted memories, fear and anxiety, and isolation from family and friends, you may have post-traumatic stress disorder. Learn about the CYPRESS research study of an investigational drug for people with PTSD.
To pre-qualify for this study, you must:
All study-related visits, tests, and drugs will be provided at no cost. In addition, reimbursement for study-related travel may be provided.
You may qualify for participation if you:
· Are 18–74 years of age
· Have been diagnosed with depression
· Have taken antidepressants in the past that did not work well for you
· Are currently taking an antidepressant medication but still have symptoms of depression
· Have difficulty falling asleep or staying asleep, or do not feel rested the next day
Do you have treatment-resistant depression (TRD)? A clinical research study is now enrolling eligible adults. The purpose of this study is to evaluate the effectiveness, safety, and tolerability of an investigational medication in people with TRD.
You may be eligible to participate if you:
If interested, additional eligibility criteria will be assessed by the study doctor or staff. The commitment for the study is about 24 weeks.
Qualified patients may receive investigational study drug and some study-required medical care at no cost.
Preferred Research Partners is enrolling adolescents with ADHD for a number of clinical study opportunities. Please enter your information to be contacted by a member of our study staff for more information to see if your child may qualify for one of our studies.
The SPARK-64 Study is looking to evaluate the effectiveness and safety of an investigational drug to see how well it works for treating constipation in 6- to 17-year-old children.
If a child in your care has been suffering from constipation, they may be eligible to take part in the SPARK-64 Study.
Your child may be eligible to take part in the SPARK-64 Study if they:
If you are 18 years of age or older and you . . .
. . . these could be symptoms of gastroparesis and you may be able to participate in this study.
If you have been diagnosed with EoE and are struggling with symptoms even while on a stable diet and medication, there may be a clinical trial for you.
Eligible participants must:
Do you suffer from symptomatic non-erosive gastroesophageal reflux disease? A clinical trial might be an option for you!
The purpose of this study, which involves research, is to
determine whether the investigational drug, vonoprazan, is safe and effective in
the potential treatment of symptomatic non-erosive gastroesophageal reflux
disease compared to a placebo.
You might qualify to participate if you have been experiencing frequent heartburn over the last six months. You must be at least 18 years old and will need to meet with a physician who is participating in this study to determine if you are fully eligible and if this study is right for you.